Author

M. De Menna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:organoid / primary culture· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

M. Kruithof-de Julio· 4 shared C. K. Ng· 2 shared F. La Manna· 2 shared G. N. Thalmann· 2 shared S. Piscuoglio· 2 shared A. Califano· 1 shared A. Dahmani· 1 shared A. Garofoli· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

M. Kruithof-de Julio

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mechano-signaling of prostate tumor initiating cells facilitates their tropism to stiff metastatic niche

L. Chen, G. Zhao, M. De Menna, S. Coppola, A. Groenewoud, N. Landman, S. Schieven, G. N. Thalmann, T. Schmidt, J. de Vrie, M. Kruithof-de Julio, E. B. Snaar

The paper shows that mechanotransduction via TAZ and cytoskeletal tension promotes prostate cancer stem cell metastasis and identifies a YAP/TAZ inhibitor as a potential therapeutic target.

bioRxiv · Aug 28, 2023 · PreprintCancer Biology

Network-based identification and pharmacological targeting of host cell master regulators induced by SARS-CoV-2 infection

P. Laise, M. L. Stanifer, G. Bosker, X. Sun, S. Triana, P. Doldan, F. La Manna, M. De Menna, R. B. Realubit, S. Pampou, C. Karan, T. Alexandrov, M. Kruithof-de Julio, A. Califano, S. Boulant, M. J. Alvarez

This study identifies host cell master regulators affected by SARS-CoV-2 and develops a method to find drugs that reverse their inactivation without harming beneficial immune responses.

bioRxiv · Jul 3, 2021Microbiology

Patient-derived xenografts and organoids model therapy response in prostate cancer

S. Karkampouna, F. La Manna, M. R. De Filippo, M. Kiener, M. De Menna, E. Zoni, J. Grosjean, I. Klima, A. Garofoli, M. Bolis, J.-P. Theurillat, V. Genitsch, D. Keller, T. Booij, C. Stirnimann, , M. Kruithof-de Julio

This study develops a patient-derived xenograft (PDX) model of prostate cancer that mimics disease stages and identifies drug sensitivities in metastatic cases.

Nature Communications · Feb 18, 2021Peer-reviewedCancer Biology

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology